Zepp Health Corp, formerly Huami, announced earlier this week that it is investing 2.4 million US Dollars to lead the 6.5 million US Dollars Series A round of funding for the development of MRI and robotics technology, which would help improve medical diagnosis.
According to a report, the investment will enable physicians to diagnose brain injury better and even help treat neurological diseases under live imaging. The Chinese consumer electronics maker will be investing in neuro42, who has an exclusive worldwide license of the low field MR imaging technology. Abhita Batra, Co-Founder and CSO of neuro42, stated that “We are pleased to have Zepp Health’s support as we revolutionize the way physicians identify and treat neurological diseases and injuries. We believe this partnership will create a compelling and sustainable value for our shareholders.”
Notably, neuro42 is Zepp Health’s third investment in new companies to develop disruptive medical imaging technologies. Recently, Zepp Health had invested in Promaxo as well, which focuses on developing office based MRI technology. Zepp Health’s Chief Operating Officer Mike Yeung also added that “Zepp Health is focused on connecting health with technology, and neuro42 is disrupting the location, applications and costs of medical imaging, which will generate tremendous benefits to healthcare systems worldwide.”
As per another executive, the company has become a global leader in consumer health technology and that these partnerships with diagnostic healthcare technologies would open up new financial and market opportunities as well to expand its business into industrial medical technology.
RELATED:
- Zepp OS: Facts about Huami’s new ultralightweight smartwatch OS
- Developing OS is as difficult as making chips, says Huami CEO Huang Wang on Zepp OS
- Top stories from last week: Xiaomi now world’s No. 2, Zepp OS, Steam Deck, Meizu’s Blue Charm returns, and more
